Inactive Instrument

CinCor Pharma, Inc.

Equities

CINC

US17240Y1091

Biotechnology & Medical Research

Shareholder Alert: Ademi LLP investigates whether CinCor Pharma, Inc. has obtained a Fair Price in its transaction with AstraZeneca

January 09, 2023 at 10:51 am

MILWAUKEE, Jan. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating CinCor (Nasdaq: CINC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca.

AdemiLogo (PRNewsfoto/Ademi LLP)

Click here to learn how to join the action https://www.ademilaw.com/case/cincor-pharma-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Ademi LLP alleges CinCor's financial outlook and prospects are excellent and yet CinCor shareholders will receive only $26 per share in cash at closing plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission of a baxdrostat product. The transaction agreement unreasonably limits competing bids for CinCor by imposing a significant penalty if CinCor accepts a superior bid. CinCor insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of CinCor's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for CinCor.

If you own CinCor common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/cincor-pharma-inc.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-cincor-pharma-inc-has-obtained-a-fair-price-in-its-transaction-with-astrazeneca-301716523.html

SOURCE Ademi LLP

Latest news about CinCor Pharma, Inc.

AstraZeneca Completes $1.8 Billion Acquisition of CinCor Pharma to Boost Cardiorenal Portfolio	23-02-24	MT
AstraZeneca closes CinCor buy; Enhertu wins Chinese approval	23-02-24	AN
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Composite Index	23-02-24	CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P Global BMI Index	23-02-24	CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P TMI Index	23-02-24	CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Biotechnology Index	23-02-23	CI
Astrazeneca Finance And Holdings Inc. completed the acquisition of CinCor Pharma, Inc. from a group of shareholders.	23-02-22	CI
CinCor Pharma, Inc. Announces Completion of End-of-Phase 2 Meeting with U.S. Food and Drug Administration on Anticipated Phase 3 Program for Baxdrostat in Hypertension	23-02-21	CI
AstraZeneca Initiates Tender Offer For $2 Billion CinCor Takeover	23-01-23	MT
ADRs End Higher; AstraZeneca, Barclays Trade Actively	23-01-23	DJ
Biotech IPO Window to Reopen in 2023 Following Muted Activity in 2022, Oppenheimer Says	23-01-23	MT
AstraZeneca Unit Starts Tender Offer to Purchase CinCor Pharma	23-01-23	MT
North American Morning Briefing : Big Day For Bank -2-	23-01-13	DJ
Barclays Downgrades CinCor Pharma to Equal-Weight Rating From Overweight, Adjusts Price Target to $31 From $22	23-01-12	MT
Morgan Stanley Adjusts Price Target on CinCor Pharma to $30 From $22, Maintains Equal-Weight Rating	23-01-10	MT
MarketScreener's World Press Review: January 10	23-01-10
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	23-01-09	DJ
Sector Update: Health Care Stocks Largely Struggle Monday	23-01-09	MT
Top Midday Gainers	23-01-09	MT
Sector Update: Health Care Stocks Struggling to Begin New Week	23-01-09	MT
FTSE 100 Closed Up Boosted by China Reopening	23-01-09	DJ
European Markets Advance as Germany Eases Recession Fears	23-01-09	MT
Global markets live: Alibaba, Qiagen, Macy's, Oracle, Chevron...	23-01-09
The return of optimism	23-01-09
Sterling to Rally if UK GDP Data Beat Forecasts	23-01-09	DJ

Chart CinCor Pharma, Inc.

Duration

Period

More charts

Company Profile

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). It also exploring its utility in ameliorating complications of CKD. It is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+25.15%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-16.68%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs